Soleno Therapeutics(SLNO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025 [18] - Full-year 2025 total net revenue was $190.4 million, with a positive net income of $20.9 million and cash flow positive with $48.7 million generated from operating activities in Q4 [5][18] - The company ended the year with over $506 million in cash equivalents and marketable securities [5][18] Business Line Data and Key Metrics Changes - VYKAT XR received 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [6][11] - Active treatment increased to 859 individuals by the end of Q4, up from 764 at the end of Q3 [11] - The cumulative launch-to-date discontinuation rate related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [7][14] Market Data and Key Metrics Changes - The company anticipates capturing an additional approximately 1,000 patient start forms over the next nine to twelve months [6] - The U.K. and EU markets are estimated to have about 9,500 individuals living with PWS, with strong support from thought leaders for VYKAT XR [9] Company Strategy and Development Direction - The company plans to expand beyond PWS into other metabolic rare disease indications, starting with Glycogen Storage Disease Type I (GSD I) [26] - The strategy includes filing an IND for GSD I in the first half of 2026 and initiating a clinical program later that year [27] - The focus remains on successful commercialization of VYKAT XR in the U.S. and exploring opportunities in the EU and other geographies [64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum and capturing additional market share for VYKAT XR, highlighting strong engagement from prescribers and caregivers [6][12] - The management acknowledged the complexities of the PWS patient population and the importance of real-world safety profiles [7][14] - The company is optimistic about the upcoming regulatory decision in the EU and potential commercialization options [8][9] Other Important Information - The company has a strong balance sheet, ensuring sufficient capital for ongoing operations and potential new indications [19] - The CFO announced retirement plans, with a successor already identified to ensure a smooth transition [25] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next nine to twelve months? - Management indicated that the start forms will come in over the year rather than in a specific quarter [31][32] Question: What percent of the market could be accessible in the U.S. for PWS? - Management suggested that higher penetration than 40%-50% is possible given the lack of other treatments [37] Question: What are the refill rates and how might the average weight of new patients change over time? - Management reported high adherence rates and expected that the average weight of new patients would likely increase over time [40][41] Question: How does the company view exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend IP beyond current patents, with potential extensions into the late 2030s [68] Question: What are the expectations for the EU approval process? - Management noted that they are awaiting Day 180 questions from the EMA and are optimistic about the approval process despite challenges [75]